{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:15:53Z","timestamp":1793193353843,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":123,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.autrev.2023.103334","type":"journal-article","created":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T18:49:03Z","timestamp":1681584543000},"page":"103334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["The interferon in idiopathic inflammatory myopathies: Different signatures and new therapeutic perspectives. A literature review"],"prefix":"10.1016","volume":"22","author":[{"given":"M.","family":"Gasparotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Zanatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ghirardello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Iaccarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2023.103334_bb0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13317-014-0060-4","article-title":"Myositis autoantibodies and clinical phenotypes","volume":"5","author":"Ghirardello","year":"2014","journal-title":"Autoimmun Highlights"},{"key":"10.1016\/j.autrev.2023.103334_bb0010","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/08916930600622645","article-title":"Clinical implications of autoantibody screening in patients with autoimmune myositis","volume":"39","author":"Ghirardello","year":"2006","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2023.103334_bb0015","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jim.2012.07.019","article-title":"Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort","volume":"384","author":"Tarricone","year":"2012","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.autrev.2023.103334_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.103013","article-title":"An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management","volume":"21","author":"Decker","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103334_bb0025","first-page":"33","article-title":"Where are we moving in the classification of idiopathic inflammatory myopathies?","author":"Tanboon","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.autrev.2023.103334_bb0030","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.mpmed.2021.10.011","article-title":"Adult idiopathic inflammatory myopathies","volume":"50","author":"Parker","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2023.103334_bb0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s13317-014-0063-1","article-title":"Assessment of patients with idiopathic inflammatory myopathies and isolated creatin-kinase elevation","volume":"5","author":"Iaccarino","year":"2014","journal-title":"Autoimmun Highlights"},{"key":"10.1016\/j.autrev.2023.103334_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103264","article-title":"The role of bDMARDs in idiopathic inflammatory myopathies: a systematic literature review","volume":"22","author":"Grazzini","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103334_bb0045","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/BOR.0000000000000653","article-title":"Interferon-signature in idiopathic inflammatory myopathies","volume":"31","author":"Gallay","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103334_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000811","article-title":"Distinct interferon signatures stratify inflammatory and dysimmune myopathies","volume":"5","author":"Rigolet","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2023.103334_bb0055","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2023.103334_bb0060","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3389\/fimmu.2018.02061","article-title":"The dual nature of type I and type II interferons. N.d","volume":"9","author":"Lee","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103334_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102763","article-title":"Interleukin 1\u03b1: a comprehensive review on the role of IL-1\u03b1 in the pathogenesis and treatment of autoimmune and inflammatory diseases","volume":"20","author":"Cavalli","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103334_bb0070","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jbspin.2009.03.012","article-title":"Interferons and autoimmune disorders","volume":"76","author":"Meyer","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2023.103334_bb0075","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.semarthrit.2012.12.026","article-title":"Plasmacytoid dendritic cells: key players in viral infections and autoimmune diseases","volume":"43","author":"Santana-de Anda","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103334_bb0080","first-page":"575","article-title":"Emerging concepts of type I interferons in SLE pathogenesis and therapy","volume":"18","author":"Psarras","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2023.103334_bb0085","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrrheum.2018.31","article-title":"Type I interferon in rheumatic diseases","volume":"14","author":"Muskardin","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2023.103334_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002687","article-title":"Interferon signature in systemic autoimmune diseases: what does it mean?","volume":"8","author":"Nocturne","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2023.103334_bb0095","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/art.21890","article-title":"Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies","volume":"54","author":"Hua","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103334_bb0100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0022-1759(96)00168-8","article-title":"A highly precise reporter gene bioassay for type I interferon","volume":"199","author":"Canosi","year":"1996","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.autrev.2023.103334_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103262","article-title":"Circulating and skin biopsy-present cytokines related to the pathogenesis of cutaneous lupus erythematosus","volume":"22","author":"Erazo-Mart\u00ednez","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103334_bb0110","article-title":"Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis","volume":"9","author":"Northcott","year":"2022","journal-title":"Lupus Sci Amp Med"},{"key":"10.1016\/j.autrev.2023.103334_bb0115","first-page":"11","article-title":"The role of interferons in the pathogenesis of Sj\u00f6gren\u2019s syndrome and future therapeutic perspectives","author":"Del Papa","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.autrev.2023.103334_bb0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and II interferon signatures in Sjogren\u2019s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren\u2019s related lymphomagenesis","volume":"63","author":"Nezos","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2023.103334_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102756","article-title":"Pathophysiologic role of Interleukin-33\/ST2 in Sj\u00f6gren\u2019s syndrome","volume":"20","author":"Soyfoo","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103334_bb0130","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.38288","article-title":"Association of Interferon- and transforming growth factor \u03b2-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis","volume":"66","author":"Christmann","year":"2014","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2023.103334_bb0135","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/annrheumdis-2019-215894","article-title":"Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile","volume":"79","author":"Skaug","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103334_bb0140","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/BOR.0000000000000831","article-title":"Lymphocyte immunophenotyping in inflammatory myositis: a review","volume":"33","author":"Franco","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103334_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.773352","article-title":"Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies","volume":"12","author":"Nombel","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103334_bb0150","doi-asserted-by":"crossref","first-page":"e29161","DOI":"10.1371\/journal.pone.0029161","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2023.103334_bb0155","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1212\/WNL.0000000000200679","article-title":"Type I interferons in dermatomyositis myoblasts","volume":"98","author":"Pinal-Fernandez","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2023.103334_bb0160","doi-asserted-by":"crossref","first-page":"32818","DOI":"10.1038\/srep32818","article-title":"Transcriptomic profiling of long non-coding RNAs in dermatomyositis by microarray analysis","volume":"6","author":"Peng","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2023.103334_bb0165","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.21805","article-title":"Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy","volume":"67","author":"Salajegheh","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2023.103334_bb0170","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13075-017-1383-0","article-title":"RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis","volume":"19","author":"Su\u00e1rez-Calvet","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103334_bb0175","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1755-8794-5-53","article-title":"Genomic signatures characterize leukocyte infiltration in myositis muscles","volume":"5","author":"Zhu","year":"2012","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.autrev.2023.103334_bb0180","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2023.103334_bb0185","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1136\/annrheumdis-2019-216599","article-title":"Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis","volume":"79","author":"Pinal-Fernandez","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103334_bb0190","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1212\/WNL.0000000000003568","article-title":"Sarcoplasmic MxA expression: a valuable marker of dermatomyositis","volume":"88","author":"Uruha","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2023.103334_bb0195","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","article-title":"239th ENMC international workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018","volume":"30","author":"Mammen","year":"2020","journal-title":"Neuromuscul Disord NMD"},{"key":"10.1016\/j.autrev.2023.103334_bb0200","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jid.2019.10.020","article-title":"MDA5+ dermatomyositis is associated with stronger skin type I interferon transcriptomic signature with upregulation of IFN-\u03ba transcript","volume":"140","author":"Cassius","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2023.103334_bb0205","doi-asserted-by":"crossref","first-page":"e04866","DOI":"10.1016\/j.heliyon.2020.e04866","article-title":"Investigating genetic drivers of dermatomyositis pathogenesis using meta-analysis","volume":"6","author":"Aljabban","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.autrev.2023.103334_bb0210","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1600-0560.2009.01443.x","article-title":"The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis","volume":"37","author":"Magro","year":"2010","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.autrev.2023.103334_bb0215","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41579-018-0020-5","article-title":"ISG15 in antiviral immunity and beyond","volume":"16","author":"Perng","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.autrev.2023.103334_bb0220","first-page":"5","article-title":"Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies","author":"Seto","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2023.103334_bb0225","doi-asserted-by":"crossref","first-page":"e2108","DOI":"10.1212\/WNL.0000000000200271","article-title":"Involvement of type I interferon signaling in muscle stem cell proliferation during dermatomyositis","volume":"98","author":"Gallay","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2023.103334_bb0230","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00401-017-1731-9","article-title":"IFN-\u03b2-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis","volume":"134","author":"Meyer","year":"2017","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1016\/j.autrev.2023.103334_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103308","article-title":"Oxidative stress, mitochondrial dysfunction, and respiratory chain enzyme defects in inflammatory myopathies","volume":"22","author":"Danieli","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103334_bb0240","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/BOR.0000000000000748","article-title":"Nonimmune mechanisms in idiopathic inflammatory myopathies","volume":"32","author":"Loredo Martinez","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103334_bb0245","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.jid.2020.12.032","article-title":"Myeloid dendritic cells are major producers of IFN-\u03b2 in dermatomyositis and may contribute to hydroxychloroquine refractoriness","volume":"141","author":"Chen","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2023.103334_bb0250","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/BOR.0000000000000908","article-title":"Anti-MDA5 dermatomyositis: an update from bench to bedside","volume":"34","author":"Fuzzi","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103334_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103161","article-title":"Friend or foe: RIG- I like receptors and diseases","volume":"21","author":"Song","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103334_bb0260","article-title":"Pathogenesis of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a concise review with an emphasis on type I interferon system","volume":"8","author":"Hu","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.autrev.2023.103334_bb0265","article-title":"RNA-containing immune complexes formed by anti-melanoma differentiation associated gene 5 autoantibody are potent inducers of IFN-\u03b1","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103334_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102831","article-title":"Monoclonal antibodies from B cells of patients with anti-MDA5 antibody-positive dermatomyositis directly stimulate interferon gamma production","volume":"130","author":"Coutant","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2023.103334_bb0275","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/bjd.16917","article-title":"Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis","volume":"180","author":"Zhang","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2023.103334_bb0280","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1038\/s41467-022-34145-4","article-title":"Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications","volume":"13","author":"Ye","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2023.103334_bb0285","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/14397595.2014.900843","article-title":"Serum interferon-\u03b1 is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis","volume":"25","author":"Horai","year":"2015","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2023.103334_bb0290","first-page":"10","article-title":"Proteomic profiling unravels a key role of specific macrophage subtypes in sporadic inclusion body myositis","author":"Roos","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103334_bb0295","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.ajpath.2011.05.055","article-title":"Inclusion body myositis: laser microdissection reveals differential up-regulation of IFN-\u03b3 signaling cascade in attacked versus nonattacked myofibers","volume":"179","author":"Ivanidze","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2023.103334_bb0300","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2023.103334_bb0305","article-title":"Interferon-gamma mediates skeletal muscle lesions through JAK\/STAT pathway activation in inclusion body myositis","author":"Hou","year":"2021","journal-title":"BioRxiv"},{"key":"10.1016\/j.autrev.2023.103334_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103204","article-title":"Two novel anti-aminoacyl tRNA synthetase antibodies: autoantibodies against cysteinyl-tRNA synthetase and valyl-tRNA synthetase","volume":"21","author":"Muro","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103334_bb0315","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/aww125","article-title":"Perifascicular necrosis in anti-synthetase syndrome beyond anti-Jo-1","volume":"139","author":"Uruha","year":"2016","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.autrev.2023.103334_bb0320","article-title":"Muscle pathology of antisynthetase syndrome according to antibody subtypes","author":"Tanboon","year":"2022","journal-title":"MedRxiv"},{"key":"10.1016\/j.autrev.2023.103334_bb0325","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/nan.12551","article-title":"Absence of sarcoplasmic myxovirus resistance protein A (MxA) expression in antisynthetase syndrome in a cohort of 194 cases","volume":"45","author":"Inoue","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.autrev.2023.103334_bb0330","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/art.24631","article-title":"Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease","volume":"60","author":"Richards","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103334_bb0335","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.ajpath.2012.08.033","article-title":"Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile","volume":"181","author":"Preu\u00dfe","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2023.103334_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102993","article-title":"Immune-mediated necrotizing myopathy (IMNM): a myopathological challenge","volume":"21","author":"Merlonghi","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103334_bb0345","first-page":"23","article-title":"Pathophysiological mechanisms and treatment of dermatomyositis and immune mediated necrotizing myopathies: a focused review","author":"Kamperman","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2023.103334_bb0350","article-title":"Necrosis in anti-SRP+ and anti-HMGCR+myopathies","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2023.103334_bb0355","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.it.2015.01.002","article-title":"The molecular basis for functional plasticity in type I interferon signaling","volume":"36","author":"Schreiber","year":"2015","journal-title":"Trends Immunol"},{"key":"10.1016\/j.autrev.2023.103334_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102785","article-title":"The revisited role of interleukin-1 alpha and beta in autoimmune and inflammatory disorders and in comorbidities","volume":"20","author":"Galozzi","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103334_bb0365","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/icb.2012.9","article-title":"The interferons and their receptors--distribution and regulation","volume":"90","author":"de Weerd","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.autrev.2023.103334_bb0370","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/376230a0","article-title":"Crystal structure of a complex between interferon-gamma and its soluble high-affinity receptor","volume":"376","author":"Walter","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2023.103334_bb0375","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/sj.cr.7310008","article-title":"Preassembly and ligand-induced restructuring of the chains of the IFN-\u03b3 receptor complex: the roles of Jak kinases, Stat1 and the receptor chains","volume":"16","author":"Krause","year":"2006","journal-title":"Cell Res"},{"key":"10.1016\/j.autrev.2023.103334_bb0380","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/ni.3212","article-title":"Guarding the frontiers: the biology of type III interferons","volume":"16","author":"Wack","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2023.103334_bb0385","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/1744666X.2021.1925541","article-title":"JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials","volume":"17","author":"Keeling","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2023.103334_bb0390","first-page":"10","article-title":"Management of rheumatoid arthritis: an overview","author":"Radu","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2023.103334_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103276","article-title":"JAK inhibitors and autoimmune rheumatic diseases","volume":"22","author":"Benucci","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103334_bb0400","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.autrev.2023.103334_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102750","article-title":"Working and safety profiles of JAK\/STAT signaling inhibitors. Are these small molecules also smart?","volume":"20","author":"Favoino","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103334_bb0410","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2023.103334_bb0415","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci Publ Protein Soc"},{"key":"10.1016\/j.autrev.2023.103334_bb0420","doi-asserted-by":"crossref","first-page":"104392","DOI":"10.1016\/j.phrs.2019.104392","article-title":"The new entries in the therapeutic armamentarium: the small molecule JAK inhibitors","volume":"147","author":"Bechman","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.autrev.2023.103334_bb0425","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103334_bb0430","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103334_bb0435","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103334_bb0440","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)","volume":"78","author":"Tanaka","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103334_bb0445","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2023.103334_bb0450","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103334_bb0455","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103334_bb0460","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/ard-2022-222608","article-title":"Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial","volume":"81","author":"van der Heijde","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103334_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103168","article-title":"JAK inhibitors and systemic sclerosis: a systematic review of the literature","volume":"21","author":"Moriana","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103334_bb0470","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103334_bb0475","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s13555-021-00517-9","article-title":"Efficacy and safety of Janus kinase inhibitors in type I interferon-mediated monogenic autoinflammatory disorders: a scoping review","volume":"11","author":"G\u00f3mez-Arias","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.autrev.2023.103334_bb0480","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jaci.2021.07.028","article-title":"JAK inhibition in the type I interferonopathies","volume":"148","author":"Crow","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2023.103334_bb0485","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002838","article-title":"JAK inhibitors and COVID-19","volume":"10","author":"Levy","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.autrev.2023.103334_bb0490","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14939","article-title":"JAK-inhibitors for dermatomyositis: a concise literature review","volume":"34","author":"Paudyal","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.autrev.2023.103334_bb0495","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2023.103334_bb0500","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis\u2013associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103334_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.103016","article-title":"Fc receptors gone wrong: a comprehensive review of their roles in autoimmune and inflammatory diseases","volume":"21","author":"Chalayer","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103334_bb0510","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722300068X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722300068X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:28:16Z","timestamp":1761600496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899722300068X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":102,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S156899722300068X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103334","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The interferon in idiopathic inflammatory myopathies: Different signatures and new therapeutic perspectives. A literature review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103334"}}